Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks why MS patients switch to kesimpta

NCT ID NCT05566756

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 307 people with relapsing multiple sclerosis in Germany who had recently switched to the drug Kesimpta (ofatumumab) from another treatment. Researchers collected information on why patients made the switch and how many doses they missed over one year. The goal was to understand real-world use of the medication, not to test if it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

  • Novartis Investigative Site

    Mannheim, Baden-Wurttemberg, 66163, Germany

  • Novartis Investigative Site

    Bamberg, Bavaria, 96052, Germany

  • Novartis Investigative Site

    Bad Homburg, Hesse, 61348, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 60313, Germany

  • Novartis Investigative Site

    Marburg, Hesse, 35043, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, 50935, Germany

  • Novartis Investigative Site

    Essen, North Rhine-Westphalia, 45134, Germany

  • Novartis Investigative Site

    Altenburg, Thuringia, 04600, Germany

  • Novartis Investigative Site

    Alzey, 55232, Germany

  • Novartis Investigative Site

    Bayreuth, 95445, Germany

  • Novartis Investigative Site

    Berlin, 12099, Germany

  • Novartis Investigative Site

    Berlin, 13347, Germany

  • Novartis Investigative Site

    Berlin, 13357, Germany

  • Novartis Investigative Site

    Bochum, 44787, Germany

  • Novartis Investigative Site

    Bogen, 94327, Germany

  • Novartis Investigative Site

    Bonn, 53111, Germany

  • Novartis Investigative Site

    Böblingen, 71032, Germany

  • Novartis Investigative Site

    Chemnitz, 09117, Germany

  • Novartis Investigative Site

    Düsseldorf, 40211, Germany

  • Novartis Investigative Site

    Düsseldorf, 40625, Germany

  • Novartis Investigative Site

    Essen, 45257, Germany

  • Novartis Investigative Site

    Gelsenkirchen, 45894, Germany

  • Novartis Investigative Site

    Giessen, 35392, Germany

  • Novartis Investigative Site

    Gladenbach, 35075, Germany

  • Novartis Investigative Site

    Hagen, 58095, Germany

  • Novartis Investigative Site

    Hamburg, 20249, Germany

  • Novartis Investigative Site

    Hamburg, 22179, Germany

  • Novartis Investigative Site

    Hanover, 30625, Germany

  • Novartis Investigative Site

    Kaiserslautern, 67655, Germany

  • Novartis Investigative Site

    Minden, 32423, Germany

  • Novartis Investigative Site

    Osnabrück, 49074, Germany

  • Novartis Investigative Site

    Pforzheim, 75172, Germany

  • Novartis Investigative Site

    Quakenbrück, 49610, Germany

  • Novartis Investigative Site

    Remscheid, 42853, Germany

  • Novartis Investigative Site

    Rülzheim, 76761, Germany

  • Novartis Investigative Site

    Siegen, 57076, Germany

  • Novartis Investigative Site

    Sinsheim, 74889, Germany

  • Novartis Investigative Site

    Stuttgart, 70174, Germany

  • Novartis Investigative Site

    Stuttgart, 70182, Germany

  • Novartis Investigative Site

    Unterhaching, 82008, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.